Photocure ASA (OSL:PHO)

Norway flag Norway · Delayed Price · Currency is NOK
63.20
-2.10 (-3.22%)
Aug 1, 2025, 4:29 PM CET
-3.22%
Market Cap1.68B
Revenue (ttm)532.69M
Net Income (ttm)2.14M
Shares Out26.61M
EPS (ttm)0.08
PE Ratio786.50
Forward PE131.67
Dividendn/a
Ex-Dividend Daten/a
Volume71,884
Average Volume77,103
Open64.80
Previous Close65.30
Day's Range62.50 - 64.80
52-Week Range47.00 - 71.80
Beta0.61
RSI57.22
Earnings DateJul 30, 2025

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]

Sector Healthcare
Founded 1993
Employees 101
Stock Exchange Oslo Børs
Ticker Symbol PHO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.